Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Reckitt Benckiser Gp (RB.)

  Print      Mail a friend       Annual reports

Monday 25 February, 2013

Reckitt Benckiser Gp

FDA Decision on Citizen's Petition-Generics App...

25 February 2013

                Reckitt Benckiser Pharmaceuticals Inc. Receives                
   FDA Response to Citizen's Petition and Announcement of Generics Approval    

Reckitt Benckiser (RB) notes that the US Food and Drug Administration (FDA) has
denied a Citizen's Petition filed by the RB Pharmaceuticals business (RBP). In
the Citizen's Petition, RBP presented a new evaluation of paediatric exposure
data and recommended that the FDA adopt more stringent packaging standards and
increased educational interventions to help reduce the number of children
exposed to buprenorphine-containing products used to treat opioid dependence.
The FDA concluded that the safety data presented by RB Pharmaceuticals did not
warrant these additional measures, deciding instead that existing labelling and
safety programmes were sufficient.

RBP is disappointed with the decision but will continue to work with the FDA on
safety enhancements. RBP remains committed to maintaining its own high level
standards for safety, including the use of child resistant, unit-dose packaging
for its buprenorphine-based opioid dependence treatment products. It will
therefore carry on with the decision to discontinue the sale of its loose
tablet bottles of SUBOXONE in the United States in favour of other effective
treatment options that have shown reduced paediatric exposure rates.

In the communication from the FDA, RBP was also informed that two unnamed
manufacturers have now received approval to produce generic SUBOXONE Tablets
buprenorphine and naloxone) Sublingual (CIII) in the US. The details of these
manufacturers' proposed safety programmes have not been provided.

RBP is a pioneer in the development of innovative prescription treatments for
the chronic diseases of addiction and introduced SUBOXONE Film (buprenorphine
and naloxone) Sublingual (CIII) in 2010 as a next generation product with
enhanced features, including unit-dose, child resistant packaging. This was in
response to patient and provider feedback and reports of misuse, abuse,
diversion and pediatric exposure associated with the buprenorphine and naloxone
tablets. RBP remains confident in the value and benefits of SUBOXONE Film as
the product is a significant advancement in product technology.

Please see full Prescribing Information at:

                                   - ENDS -                                    

For questions please contact:

Investors & Analyst Queries                      +44 (0)1753 217800          
Richard Joyce                                                                
Director, Investor Relations                                                 
UK Media Queries                                 +44 (0)1753 217800          
Andraea Dawson-Shepherd                                                      
                                                 +44 (0)20 7404 5959         
SVP, Global Corporate Communication and Affairs                              
David Litterick / Max McGahan                                                
Brunswick Financial PR                                                       
USA Medical Media Queries                        +1 (0) 804 594 0836         
Reckitt Benckiser Pharmaceutical Media Contacts  RBPMediaContacts@           
USA Patient or Doctor Queries                                                
                                                 +1 (0) 866 973 4373         
For Patient Queries                                                          
                                                 +1 (0) 877 782 6966         
For Doctor Queries

a d v e r t i s e m e n t